These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 9123406)

  • 21. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action.
    Jordan SC; Quartel AW; Czer LS; Admon D; Chen G; Fishbein MC; Schwieger J; Steiner RW; Davis C; Tyan DB
    Transplantation; 1998 Sep; 66(6):800-5. PubMed ID: 9771846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Detection of HLA class I and II antibodies by ELISA and complement-dependent cytotoxicity before and after transplantation.
    Christiaans MH; Nieman F; van Hooff JP; van den Berg-Loonen EM
    Transplantation; 2000 Mar; 69(5):917-27. PubMed ID: 10755551
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Soluble MHC class I antigens (sHLA) and anti-HLA antibodies in heart and kidney allograft recipients.
    Zavazava N; Böttcher H; Ruchholtz WM
    Tissue Antigens; 1993 Jul; 42(1):20-6. PubMed ID: 8248891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Harmful effect of preformed anti-MICA antibodies on renal allograft evolution in early posttransplantation period.
    Sánchez-Zapardiel E; Castro-Panete MJ; Castillo-Rama M; Morales P; Lora-Pablos D; Valero-Hervás D; Ruiz-García R; Apaza J; Talayero P; Andrés A; Morales JM; Paz-Artal E
    Transplantation; 2013 Jul; 96(1):70-8. PubMed ID: 23624543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Absence of irreversible rejection in the presence of warm anti-donor-HLA class I cytotoxic IgG antibody.
    Shoker A; Klassen J; Herbut B
    Clin Nephrol; 1997 Feb; 47(2):87-91. PubMed ID: 9049455
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-human leukocyte antigen antibodies reactive with endothelial cells could be involved in early loss of renal allografts.
    Ronda C; Borba SC; Ferreira SC; Glotz D; Ianhez LE; Rodrigues H; Viggiani CS; Nahas W; David-Neto E; Castro MC; David Daisa SR; Kalil J; Panajotopoulos N
    Transplant Proc; 2011 May; 43(4):1345-8. PubMed ID: 21620126
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal transplantation in 2016: Novel approaches to improve recipient and allograft outcomes.
    Malvezzi P; Rostaing L
    Nat Rev Nephrol; 2017 Jan; 13(2):73-74. PubMed ID: 28100905
    [No Abstract]   [Full Text] [Related]  

  • 28. Frequency of MIC antibody in rejected renal transplant patients without HLA antibody.
    Mizutani K; Terasaki PI; Shih RN; Pei R; Ozawa M; Lee J
    Hum Immunol; 2006 Mar; 67(3):223-9. PubMed ID: 16698446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Soluble HLA and anti-idiotypic antibodies in transplantation: modulation of anti-HLA antibodies by soluble HLA antigens from the graft and anti-idiotypic antibodies in renal and cardiac allograft recipients.
    Suciu-Foca N; Ho E; King DW; Yu YP; Yu-Kai S; Reed E; Cohen D; Brensilver JM; McCabe R; Rose E
    Transplant Proc; 1991 Feb; 23(1 Pt 1):295-6. PubMed ID: 1990536
    [No Abstract]   [Full Text] [Related]  

  • 30. Post-transplant immune serological markers may be predictive of chronic rejection.
    Kerman RH
    Ann Transplant; 2000; 5(2):24-8. PubMed ID: 11217203
    [No Abstract]   [Full Text] [Related]  

  • 31. Association of kidney transplant failure and antibodies against MICA.
    Mizutani K; Terasaki P; Bignon JD; Hourmant M; Cesbron-Gautier A; Shih RN; Pei R; Lee J; Ozawa M
    Hum Immunol; 2006 Sep; 67(9):683-91. PubMed ID: 17002898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Posttransplant peripheral blood donor-specific interferon-γ enzyme-linked immune spot assay differentiates risk of subclinical rejection and de novo donor-specific alloantibodies in kidney transplant recipients.
    Crespo E; Cravedi P; Martorell J; Luque S; Melilli E; Cruzado JM; Jarque M; Meneghini M; Manonelles A; Donadei C; Lloberas N; Gomà M; Grinyó JM; Heeger P; Bestard O
    Kidney Int; 2017 Jul; 92(1):201-213. PubMed ID: 28274484
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Formation of donor-specific human leukocyte antigen antibodies after kidney transplantation: correlation with acute rejection and tapering of immunosuppression.
    van der Mast BJ; van Besouw NM; Witvliet MD; de Kuiper P; Smak Gregoor P; van Gelder T; Weimar W; Claas FH
    Transplantation; 2003 Mar; 75(6):871-7. PubMed ID: 12660517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Presensitized kidney graft recipients with HLA class I and II antibodies are at increased risk for graft failure: a Collaborative Transplant Study report.
    Süsal C; Döhler B; Opelz G
    Hum Immunol; 2009 Aug; 70(8):569-73. PubMed ID: 19375472
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence and prediction of early antibody-mediated rejection due to non-human leukocyte antigen-antibodies.
    Amico P; Hönger G; Bielmann D; Lutz D; Garzoni D; Steiger J; Mihatsch MJ; Dragun D; Schaub S
    Transplantation; 2008 Jun; 85(11):1557-63. PubMed ID: 18551059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant human erythropoietin decreases anti-HLA sensitization and may improve renal allograft outcome: involvement of anti-idiotypic antibody.
    Grimm PC; Sekiya NM; Robertson LS; Robinson BJ; Ettenger RB
    Transplant Proc; 1991 Feb; 23(1 Pt 1):407-8. PubMed ID: 1990568
    [No Abstract]   [Full Text] [Related]  

  • 37. Association between the presence of anti-HLA antibodies with acute rejection and chronic allograft nephropathy in the first year after kidney transplantation.
    Toresan R; Manfro RC; Proença MC; Veronese FJ; Salim PH; da Silva DM; Ribeiro AR; Edelweiss MI; Pegas KL; Jobim LF
    Transplant Proc; 2008 Apr; 40(3):718-9. PubMed ID: 18454996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allosensitization to HLA and MICA is an important measure of renal graft outcome.
    Panigrahi A; Siddiqui JA; Rai A; Margoob A; Khaira A; Bhowmik D; Tiwari SC; Guleria S; Mehra NK
    Clin Transpl; 2007; ():211-7. PubMed ID: 18637472
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specific anti-HLA antibody immunoadsorption with columns of fibroblasts or membrane proteins coupled to microcarriers--methodology.
    Jolimoy C; Rivat C; Regnault V; Mousson C; Guignier F; Voisin P; Stoltz JF; Rifle G
    Transplant Proc; 1995 Apr; 27(2):1667-8. PubMed ID: 7725444
    [No Abstract]   [Full Text] [Related]  

  • 40. Detection of clinically relevant antibodies pretransplant and posttransplant with PRA-STAT. The Anti-CD45 Study Group.
    Neylan J; de Smet W; Stijlemans B; Brinker K; Gonwa T; Moran J; Segers A
    Transplant Proc; 1997; 29(1-2):330-2. PubMed ID: 9123025
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.